Test drug PM14 alone and with radiation for soft-tissue sarcoma
Part of Cancer clinical trials.
This early-phase study tests PM14 (a new cancer treatment) to see if it can shrink tumors in soft-tissue sarcoma. Some people also receive radiation, aiming to improve tumor control while keeping side effects manageable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18–75 years old and sign consent before extra study tests.
- You must have measurable advanced or high-risk sarcoma that has grown within 6 months.
- You must have had up to two prior chemotherapy treatments for advanced disease (if allowed for you).
- You need good blood counts, organ function (kidneys/liver), and heart pumping ability (LVEF ≥ 50%).
- You must have a central venous catheter for PM14 and be able to attend study visits/tests.
- If you can become pregnant, you must use effective birth control and have a negative pregnancy test.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new type of radiation therapy for advanced soft tissue sarcoma that has not responded to other treatments. The goal is to see if this therapy can shrink tumors and help control the cancer.
This Phase 1 trial tests PM54, a study drug, in people with advanced (cancer that has spread) solid tumors when standard treatments are no longer working. It focuses on safety and early signs of how well the treatment may work in specific cancer types.
This trial tests whether a type of chemotherapy called pegylated liposomal doxorubicin (PLD) can help keep advanced soft tissue sarcoma from growing after successful first treatment with standard anthracycline-based chemo. You may be eligible if you've completed 4-8 cycles of that initial chemo and your disease is controlled (shrank or stable).
This trial tests a new type of radiation called spatially fractionated radiation therapy (SFRT) given before surgery for large soft tissue sarcomas in the arm, leg, or trunk. The goal is to see if it helps shrink the tumor and improve treatment outcomes.
This trial studies a high-dose, shortened course of proton beam radiation for people with soft tissue sarcoma that cannot be removed by surgery. It aims to improve tumor control while reducing side effects.
This study tests whether giving radiation, chemotherapy, and immunotherapy together can control high-risk soft tissue sarcoma that is hard to remove or may come back after surgery. It may help by attacking cancer in different ways, including boosting the immune system.
Hear when a new Advanced Soft-tissue Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.